lorazepam
Boxed Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Risks of abuse, misuse, and addiction, which can lead to overdose and death. Physical dependence and life-threatening withdrawal reactions.
Lorazepam is an intermediate-acting benzodiazepine approved for anxiety disorders and as a pre-anesthetic. It has no active metabolites and is metabolized by glucuronidation, making it preferred in patients with hepatic impairment or in the elderly.
0.5mg, 1mg, 2mg
Tablets: 0.5mg, 1mg, 2mg; Oral concentrate: 2mg/mL; Injection: 2mg/mL, 4mg/mL
Category D (positive evidence of risk)
Positive allosteric modulator at GABA-A receptors. Binds to the benzodiazepine site and enhances GABA-mediated chloride conductance, producing anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
Medium half-life benzo. Crossover to diazepam often recommended for smoother taper. Liquid formulation available.
Ashton Manual recommends crossover to diazepam for gradual taper. Never stop abruptly — seizure risk.
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Crossover to diazepam (optional) | 2-4 weeks | Some prescribers recommend converting to diazepam for a smoother taper, per the Ashton Manual. |
| Initial reductions | 2-4 weeks per step | Small, gradual reductions. Your prescriber may recommend oral concentrate for precision. |
| Middle reductions | 2-4 months | Lorazepam's medium half-life means interdose fluctuations are possible. Your prescriber may split doses for more even coverage. |
| Final reductions | 2-4 months | Oral concentrate allows the most precise adjustments. The final stretch is the most challenging. |
12-24 hours after reduction (faster than Klonopin due to shorter half-life)
3-7 days
2-6 weeks for acute symptoms
Anxiety rebound, insomnia, and depersonalization may persist 3-12 months. Shorter half-life than Klonopin means somewhat faster acute resolution but protracted symptoms are similar.
Practical insights shared by members tapering Ativan. Not medical advice — always consult your prescriber.
Toxicity
CNS and respiratory depression, especially with opioids or alcohol. Physical dependence with chronic use. Abrupt discontinuation can cause seizures, psychosis, and death.
Pharmacokinetics
Well absorbed after oral administration. Bioavailability ~90%. Tmax ~2 hours. Food may slow absorption but does not reduce bioavailability.
~1.3 L/kg
Hepatic via glucuronidation (UGT) to the inactive lorazepam glucuronide. Does NOT undergo CYP-mediated oxidative metabolism, making it preferred in hepatic impairment.
Renal (~88% as glucuronide conjugate). Less than 1% excreted unchanged in urine.
~85%
~1.1 mL/min/kg
Browse our map of deprescribing-informed providers worldwide.